Human Genome Epidemiology Literature Finder
Records 1 - 2 (of 2 Records) |
Query Trace: Hyperbilirubinemia and UGT1A9[original query] |
---|
Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Feb . Peer CJ, Sissung TM, Kim A, Jain L, Woo S, Gardner ER, Kirkland CT, Troutman SM, English BC, Richardson ED, Federspiel JD, Venzon D, Dahut B, Kohn EC, Kummar S, Yarchoan R, Giaccone G, Widemann BC, Figg WD |
Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity. Pharmacogenomics 2016 09 17 (14): 1483-90. Bins Sander, Lenting Anne, El Bouazzaoui Samira, van Doorn Leni, Oomen-de Hoop Esther, Eskens Ferry Alm, van Schaik Ron Hn, Mathijssen Ron |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 16, 2024
- Content source: